• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Identifying Barriers to Developing Expertise in Hidradenitis Suppurativa.确定化脓性汗腺炎专业技能发展的障碍
J Clin Aesthet Dermatol. 2023 Sep;16(9):38-40.
2
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.皮肤科和性病科在莫斯塔尔临床医院用阿达木单抗治疗两例化脓性汗腺炎。
Acta Dermatovenerol Croat. 2021 Jul;29(2):108-110.
3
Expert Practices in Hidradenitis Suppurativa Flare Management: A Cross-Sectional Survey Study.化脓性汗腺炎发作管理的专家实践:一项横断面调查研究。
Skin Appendage Disord. 2024 Jun;10(3):224-228. doi: 10.1159/000536094. Epub 2024 Jan 24.
4
Emerging drugs for the treatment of hidradenitis suppurativa.用于治疗化脓性汗腺炎的新兴药物。
Expert Opin Emerg Drugs. 2020 Sep;25(3):201-211. doi: 10.1080/14728214.2020.1787984. Epub 2020 Jul 22.
5
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts.化脓性汗腺炎患者新冠疫苗接种指南:专家修改后的德尔菲共识
Skin Appendage Disord. 2022 Jul;8(4):287-290. doi: 10.1159/000521268. Epub 2022 Jan 10.
6
Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.化脓性汗腺炎结局评估工具和分期系统的评价者间信度和可靠性。
Br J Dermatol. 2019 Sep;181(3):483-491. doi: 10.1111/bjd.17716. Epub 2019 Jun 6.
7
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.未满足的临床需求和疾病负担:来自欧盟 5 国和美国的真实世界经验。
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1597-1605. doi: 10.1111/jdv.18163. Epub 2022 May 9.
8
Hidradenitis suppurativa for the nondermatology clinician.非皮肤科临床医生的化脓性汗腺炎
Proc (Bayl Univ Med Cent). 2020 Jul 27;33(4):586-591. doi: 10.1080/08998280.2020.1793643.
9
Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.基于欧洲化脓性汗腺炎指南的化脓性汗腺炎/反向性痤疮循证治疗方法
Rev Endocr Metab Disord. 2016 Sep;17(3):343-351. doi: 10.1007/s11154-016-9328-5.
10
Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019.第四届化脓性汗腺炎进展研讨会报告 2019 年。
J Am Acad Dermatol. 2021 Jan;84(1):120-129. doi: 10.1016/j.jaad.2020.05.114. Epub 2020 Jun 1.

本文引用的文献

1
Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System.化脓性汗腺炎的延误诊断及其对患者和医疗保健系统的影响。
Dermatology. 2020;236(5):421-430. doi: 10.1159/000508787. Epub 2020 Jul 1.
2
Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice.化脓性汗腺炎的医学和手术治疗:国际治疗指南综述及在普通皮肤科实践中的应用。
Dermatology. 2020;236(5):393-412. doi: 10.1159/000507323. Epub 2020 May 14.
3
Hidradenitis suppurativa.化脓性汗腺炎。
Nat Rev Dis Primers. 2020 Mar 12;6(1):18. doi: 10.1038/s41572-020-0149-1.
4
Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event.识别化脓性汗腺炎的护理和研究障碍:患者参与活动的结果
Br J Dermatol. 2020 Jun;182(6):1490-1492. doi: 10.1111/bjd.18818. Epub 2020 Jan 29.
5
Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis.化脓性汗腺炎:流行病学、临床表现和发病机制。
J Am Acad Dermatol. 2020 May;82(5):1045-1058. doi: 10.1016/j.jaad.2019.08.090. Epub 2019 Oct 9.
6
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.评估化脓性汗腺炎患者的未满足需求:来自全球影响和医疗需求调查(VOICE)项目的结果。
J Am Acad Dermatol. 2020 Feb;82(2):366-376. doi: 10.1016/j.jaad.2019.06.1301. Epub 2019 Jul 3.
7
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.北美化脓性汗腺炎临床管理指南:美国和加拿大化脓性汗腺炎基金会的出版物:第一部分:诊断、评估和补充及程序管理的应用。
J Am Acad Dermatol. 2019 Jul;81(1):76-90. doi: 10.1016/j.jaad.2019.02.067. Epub 2019 Mar 11.
8
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.北美化脓性汗腺炎临床管理指南:美国和加拿大化脓性汗腺炎基金会联合发布:第二部分:局部、皮损内和全身医学治疗。
J Am Acad Dermatol. 2019 Jul;81(1):91-101. doi: 10.1016/j.jaad.2019.02.068. Epub 2019 Mar 11.
9
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment.化脓性汗腺炎:诊断与治疗进展。
JAMA. 2017 Nov 28;318(20):2019-2032. doi: 10.1001/jama.2017.16691.
10
Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment.化脓性汗腺炎:发病机制与治疗综述
J Drugs Dermatol. 2016 Aug 1;15(8):1017-22.

确定化脓性汗腺炎专业技能发展的障碍

Identifying Barriers to Developing Expertise in Hidradenitis Suppurativa.

作者信息

Schukow Casey, Townsend Clare, Jess Nicole, Daveluy Steven

机构信息

Dr. Schukow is with the Department of Pathology at Corewell Health in Royal Oak, Michigan.

Dr. Townsend is with the Boston Medical Center in Boston, Massachusetts.

出版信息

J Clin Aesthet Dermatol. 2023 Sep;16(9):38-40.

PMID:37720198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10503938/
Abstract

BACKGROUND

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of hair-bearing intertriginous areas with a profound impact on quality of life.

OBJECTIVE

We sought to determine what barriers to treatment exist among both HS experts and non-experts.

METHODS

An IRB-approved, anonymous, voluntary survey was distributed to dermatologists through the HS Foundation listserv from June to September 2021.

RESULTS

Eighty-eight total responses were collected from 49 (55.7%) experts and 39 (44.3%) non-experts. Statistically significant differences were found in the comfort level of treating moderate (=0.0001) to severe (<0.0001) disease between experts and non-experts, as well as interest in treating moderate (=0.0001) and severe (<0.0001) disease. Multiple barriers to developing expertise were identified (e.g., access to necessary equipment). HS experts also indicated higher levels of knowledge and experience than non-experts with several medical treatments (e.g., IV Ertapenem, <0.0001).

LIMITATIONS

We were unable to calculate response rate since listserv survey recipients were encouraged to share the survey through their personal networks.

CONCLUSION

This data demonstrates statistically significant differences in levels of comfort and interest between experts and non-experts in treating moderate to severe disease, as well as differences in medical therapies utilized. Furthermore, multiple barriers to expertise were identified by both experts and non-experts.

摘要

背景

化脓性汗腺炎(HS)是一种累及有毛发的褶皱部位的慢性炎症性疾病,对生活质量有深远影响。

目的

我们试图确定HS专家和非专家在治疗方面存在哪些障碍。

方法

2021年6月至9月,通过HS基金会的邮件列表向皮肤科医生发放了一份经机构审查委员会批准的匿名自愿调查问卷。

结果

共收集到88份回复,其中49份(55.7%)来自专家,39份(44.3%)来自非专家。专家和非专家在治疗中度(=0.0001)至重度(<0.0001)疾病的舒适度以及治疗中度(=0.0001)和重度(<0.0001)疾病的兴趣方面存在统计学显著差异。确定了发展专业知识的多个障碍(例如,获得必要设备)。HS专家在几种医学治疗方法(如静脉注射厄他培南,<0.0001)方面也比非专家表现出更高的知识水平和经验。

局限性

由于鼓励邮件列表调查的收件人通过其个人网络分享调查,我们无法计算回复率。

结论

该数据表明,专家和非专家在治疗中度至重度疾病的舒适度和兴趣水平上存在统计学显著差异,以及在使用的医学疗法上也存在差异。此外,专家和非专家都确定了专业知识方面的多个障碍。